^
    10ms
    MAGIC-G1: A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, Biodexa Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    panobinostat (MTX110)
    1year
    CED of MTX110 Newly Diagnosed Diffuse Midline Gliomas (clinicaltrials.gov)
    P1, N=9, Completed, Luca Szalontay | Recruiting --> Completed
    Trial completion
    |
    panobinostat (MTX110)
    over1year
    Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults With Recurrent Medulloblastoma (clinicaltrials.gov)
    P1, N=5, Recruiting, The University of Texas Health Science Center, Houston | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    panobinostat (MTX110)
    over1year
    PNOC015: Repeated convection enhanced delivery (CED) of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). (PubMed, Neuro Oncol)
    Repeat CED of MTX110 with real time imaging with gadoteridol is tolerable for patients with DIPG. Median OS of 26.1 months compares favorably with historical data for children with DIPG. The results support further investigation of this strategy in a larger cohort.
    Journal
    |
    Farydak (panobinostat) • panobinostat (MTX110)
    3years
    Efficacy of soluble panobinostat (MTX110) in preclinical models of adult glioblastoma (SNO 2021)
    In vivo MTX110 in combination with radiation treatment showed an enhanced delay in tumor growth of approximately 50% compared to MTX110 or radiation alone. The results are supportive of the planned exploratory trial in GBM with MTX110.
    Preclinical
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation
    |
    Farydak (panobinostat) • panobinostat (MTX110)